| Barrow Hanley Global Share Fund (Managed Fund) (GLOB) |
Financials |
$481 |
Quarterly Portfolio Disclosure - June 2025
|
29 Aug 2025 9:44AM |
$4.800 |
$4.580 |
fallen by
4.58%
|
|
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$28 |
Appendix 4E and Annual Report
|
29 Aug 2025 9:44AM |
$0.064 |
$0.075 |
risen by
17.19%
|
|
BDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss for the year: $7.2 million
- Total assets: $9.9 million
- Total liabilities: $3.7 million
- Decrease in cash and cash equivalents to $4.5 million
- Issued 43 million shares raising $4.3 million
- Contributed equity at year-end: $33.8 million
- Major shareholders include Capital Property Corporation and Nabelle Pty Ltd
- Unutilized tax losses: $13.8 million
- Details of financial instruments and lease liabilities
- Key management personnel remuneration and shareholdings
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$28 |
Appendix 4E and Annual Report
|
29 Aug 2025 9:44AM |
$0.064 |
$0.075 |
risen by
17.19%
|
|
BDX - Price-sensitive ASX Announcement
Full Release
Key Points
- BCAL Diagnostics Limited launched its first commercial product, BREASTESTplus™, in the Australian market.
- The product addresses the diagnostic challenge of detecting tumors in women with high breast density.
- 107 tests were sold by June 30, 2025, reflecting commercial traction and clinical validation.
- The company established a strategic partnership with Cancer Care Associates and the Sydney Breast Clinic.
- BCAL Diagnostics has filed a third Australian patent and expanded its intellectual property portfolio.
- The company closed FY2025 with a cash balance of $4.5 million.
- Revenue primarily comprises the R&D tax offset with an estimated claim of $2.5 million for 2025.
- BCAL Diagnostics is focusing on expanding BREASTESTplus™ in Australia and preparing for the US market entry.
- BCAL recorded a net loss of $7,241,035 for the year ended June 30, 2025.
- The company incorporated a wholly owned subsidiary in North Carolina, USA, for R&D expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jayride Group Limited (JAY) ORDINARY FULLY PAID |
Industrials |
$9 |
Preliminary Final Report
|
29 Aug 2025 9:42AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
JAY - Price-sensitive ASX Announcement
Full Release
Key Points
- Jayride Group Limited reported a total revenue of $2,423,121 for the financial year ending 30 June 2025.
- The company experienced a comprehensive loss of $5,725,322 for the year.
- Net cash used in operating activities amounted to $1,474,395.
- There was a significant decrease in net liability equity, totaling $(6,380,722) at the end of the financial year.
- The basic and diluted loss per share was reported as (1.05) cents.
- Capitalised technology costs faced a complete write-down, resulting in impairment costs of $2,898,346.
- The company issued shares to raise capital, resulting in a total issued capital of $47,502,291.
- Jayride Group Limited had significant operating costs, including advertising and marketing expenses totaling $795,584.
- Current liabilities exceeded current assets, highlighting financial challenges for the company.
- The company did not incur any income tax expenses for the financial year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jayride Group Limited (JAY) ORDINARY FULLY PAID |
Industrials |
$9 |
Preliminary Final Report
|
29 Aug 2025 9:42AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
JAY - Price-sensitive ASX Announcement
Full Release
Key Points
- The total revenue for Jayride Group Limited decreased by 55.5% to $2,423,121 compared to the previous year.
- The loss after income tax for the year ended 30 June 2025 was $5,725,322, a decrease of 30.7% from the previous year.
- Net tangible assets per ordinary security were recorded at -0.45 cents.
- No dividends were paid, recommended, or declared during the current or previous financial period.
- The company issued 1,427,179,974 ordinary shares, with a significant increase due to the conversion of convertible notes.
- Impairment testing led to the complete write-down of technology assets, totaling an impairment recognition of $2,898,346 in the previous financial year.
- The weighted average number of ordinary shares increased significantly, impacting the loss per share calculations.
- The financial statements are in the process of being audited, with an anticipated unqualified audit opinion including a going concern paragraph.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$75 |
FY25 Results
|
29 Aug 2025 9:42AM |
$0.165 |
$0.084 |
fallen by
49.09%
|
|
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,540 |
Appendix 4E - Preliminary Final Report
|
29 Aug 2025 9:42AM |
$0.480 |
$4.250 |
risen by
785.42%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating revenue increased by 56% primarily from SaaS.
- Net loss improved to $30.1 million from the previous year.
- Other income primarily from government grants and R&D incentives.
- Imbio acquisition contingent consideration remeasurement led to $7.3 million in gains.
- Slight increase in operating expenses due to commercialization investments.
- Share placements and funding agreements to support growth and regulatory efforts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,540 |
Appendix 4E - Preliminary Final Report
|
29 Aug 2025 9:42AM |
$0.480 |
$4.250 |
risen by
785.42%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating revenue increased by 56% to $5.9 million.
- Net loss reported at $30.1 million, improving from the previous year.
- Significant SaaS revenue contribution.
- Acquisition of Imbio Inc. and related earn-outs recognized.
- Capital raised through share placements and purchase plans.
- Secured a $10 million funding with Pro Medicus Limited.
- Government grants supporting R&D activities.
- Focus on regulatory clearance for medical technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perpetual Ethical SRI Fund (Managed Fund) (GIVE) |
Financials |
$13 |
Quarterly Portfolio Disclosure - June 2025
|
29 Aug 2025 9:41AM |
$3.210 |
$2.890 |
fallen by
9.97%
|
|
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$75 |
FY25 Appendix 4E Preliminary Final Report
|
29 Aug 2025 9:39AM |
$0.165 |
$0.084 |
fallen by
49.09%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Bubs Australia Limited reported a profit of AUD 5.54 million for the financial year ending 30 June 2025.
- Total comprehensive income for FY25 was AUD 5.17 million, accounting for other comprehensive loss.
- Net cash from operating activities was positive at AUD 6.13 million, a significant improvement from the previous year's outflow.
- Issued capital remained unchanged at AUD 356.76 million as of 30 June 2025.
- The company focused on improving cash flow and reducing liabilities, with total liabilities dropping significantly from AUD 29.88 million to AUD 14.69 million.
- Share-based payments were utilized, with a reserve increase from AUD 12.26 million to AUD 12.69 million.
- The net assets of the company increased from AUD 36.87 million to AUD 42.48 million.
- Foreign currency translation reserve showed a loss, highlighting some impact from currency fluctuations.
- Receipts from customers rose to AUD 103.75 million, indicating increased sales and market activity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flynn Gold Limited (FG1) ORDINARY FULLY PAID |
Materials |
$12 |
$130,000 in Grant Funding for Drilling at Mangana and Henty
|
29 Aug 2025 9:39AM |
$0.027 |
$0.020 |
fallen by
25.93%
|
|
FG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Flynn Gold Limited (ASX: FG1) secured $130,000 in grant funding from the Tasmanian Government's Exploration Drilling Grant Initiative (EDGI).
- The funding is aimed at supporting drill testing at the Mangana Project and the Henty South Project in Tasmania.
- Mangana Project involves drilling two diamond drill holes totaling 400 meters beneath the historic Golden Entrance mine.
- Henty South Project includes a plan to drill one 500-meter diamond hole targeting a coincident gravity and IP anomaly.
- The Mangana Project targets high-grade gold beneath historic workings that have not been drill tested for a century.
- The EDGI program is a Tasmanian State Government initiative to stimulate greenfield exploration.
- The Mangana Goldfield produced approximately 6,700 ounces of gold from 1852 to 1910.
- The Golden Entrance mine was historically the richest producer in the Mangana Goldfield.
- Preparatory activities for drilling at both projects are currently underway.
- Flynn Gold owns and controls the exploration licenses through its subsidiary, Kingfisher Exploration Pty Ltd.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dorsavi Ltd (DVL) ORDINARY FULLY PAID |
Health Care |
$43 |
DVL June 2025 Appendix 4E
|
29 Aug 2025 9:38AM |
$0.047 |
$0.035 |
fallen by
25.53%
|
|
DVL - Price-sensitive ASX Announcement
Full Release
Key Points
- DorsaVi Limited reported a loss after tax of $1,517,753 for the year ending 30 June 2025.
- Total comprehensive loss for the year was $1,542,059.
- The company raised $3,169,615 through equity contributions.
- Revenues from contracts with customers were $1,129,493.
- Cash and cash equivalents at year-end were $2,293,549.
- No dividends were declared in the financial year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dorsavi Ltd (DVL) ORDINARY FULLY PAID |
Health Care |
$43 |
DVL June 2025 Appendix 4E
|
29 Aug 2025 9:38AM |
$0.047 |
$0.035 |
fallen by
25.53%
|
|
DVL - Price-sensitive ASX Announcement
Full Release
Key Points
- DorsaVi Limited is a listed public company based in Melbourne, Australia.
- The preliminary final report is presented in Australian dollars.
- Revenue from contracts with customers for 2025 was $1,129,493, a decrease from $1,304,238 in 2024.
- The company reported a loss after income tax benefit of $1,517,753 for the year ended 30 June 2025.
- Total comprehensive income for the year was negative $1,542,059.
- Total equity at 30 June 2025 was $2,835,656, compared to $1,023,350 at 30 June 2024.
- Cash and cash equivalents increased to $2,293,549 by the end of the financial year.
- There were no dividends paid or declared during the financial year.
- On 4 July 2025, the company issued 70,000,000 shares raising $910,000 before transaction costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hubify Limited (HFY) ORDINARY FULLY PAID |
Communication Services |
$6 |
Appendix 4G & Corporate Governance Statement
|
29 Aug 2025 9:38AM |
$0.008 |
$0.011 |
risen by
37.50%
|
|
| Caprice Resources Limited (CRS) ORDINARY FULLY PAID |
Materials |
$73 |
Cleansing Notice
|
29 Aug 2025 9:37AM |
$0.088 |
$0.084 |
fallen by
4.55%
|
|
| Aspen Group (APZ) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,202 |
Proposed issue of securities - APZ
|
29 Aug 2025 9:37AM |
$4.320 |
$5.280 |
risen by
22.22%
|
|
| Magnum Mining and Exploration Limited (MGU) ORDINARY FULLY PAID |
Materials |
$18 |
HIGH-GRADE RARE EARTH LEACH TESTING BEGINS
|
29 Aug 2025 9:37AM |
$0.007 |
$0.006 |
fallen by
21.43%
|
|
MGU - Price-sensitive ASX Announcement
Full Release
Key Points
- Leach testing of high-grade samples from Palmares REE Project has commenced.
- Palmares REE Project spans 18 tenements covering ~348km² in Bahia State, Brazil.
- Trench assays at Feirinha Prospect returned up to 1.69% TREO.
- Rock chip assays showed up to 1.31% TREO, enriched in Nd and Pr.
- G2 pegmatites are the main host rocks with consistent high-grade mineralization.
- 15 samples dispatched to ALS Laboratories for leach testing.
- Palmares is positioned within a region with district-scale potential for REE.
- Magnum is one of the largest landholders for REE in the region.
- Leach testing results expected by September end.
- Potential for Palmares as a significant REE project, pending testing results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$12 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.069 |
$0.036 |
fallen by
47.83%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 global sales revenue of A$7.3 million, up 49% from the prior year.
- North American Travelan® sales reached A$2.0 million, a 76% increase.
- Profit from hyperimmune products remained A$1.35 million.
- Increased selling and marketing investment by A$1.4 million.
- Focus on oral immunotherapeutics for gut-mediated diseases.
- Anticipates FDA Phase 2 meeting for Travelan® and IND approval for IMM-529 by end 2025.
- Australian launch of ProIBS planned for Q1 2026.
- Continued quarter-on-quarter growth of Travelan®.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$12 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.069 |
$0.036 |
fallen by
47.83%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 Global Sales Revenue was A$7.3 million, up 49% from the previous year.
- North American Travelan® sales increased by 76% to A$2.0 million.
- Profit from Hyperimmune products remained A$1.35 million, consistent with FY24.
- Increased investment in selling and marketing by A$1.4 million.
- Launch of ProIBS in Australia is scheduled for Q1 CY2026.
- Travelan® IMM-124E: Scheduled End of Phase 2 FDA meeting in 1H 2026.
- Anticipated FDA approval of IMM-529 (CDI) IND in December 2025.
- Immuron is a biopharmaceutical company focused on oral immunotherapeutics for gut mediated diseases.
- Cash & Term Deposit as of 30 June 2025 stood at A$5.9 million, excluding A$2.8 million raised from US placement in July 2025.
- Major shareholders include BNY Mellon Asset Management with 42.29% ownership.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$21 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.098 |
$0.075 |
fallen by
23.47%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue was $172.0 million, a 1% decrease from the prior period.
- EBITDA was reported at $12.0 million, in line with guidance.
- Normalised EBITDA increased by 4.8% to $19.5 million.
- Net Loss After Tax was $5.2 million compared to a minor loss last year.
- Revenue growth in Australia/New Zealand driven by Bunnings and grain storage.
- Revenue in developing markets increased by 14.4%.
- Challenges faced in the Americas due to tariffs and weak consumer confidence.
- Non-recurring costs included $5.4 million from D365 implementation and executive changes.
- Focus on market development and cost reduction, especially in the US and emerging markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$21 |
FY25 Results Presentation
|
29 Aug 2025 9:36AM |
$0.098 |
$0.075 |
fallen by
23.47%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue at $172 million, down 1% from prior year.
- EBITDA was $12 million, consistent with guidance.
- Net loss after tax was $5.2 million.
- Australian and New Zealand markets showed 7.6% revenue increase.
- Americas revenue declined by 11.3%, affected by tariffs and consumer sentiment.
- Developing markets like the Middle East, Europe, and Asia showed growth.
- Significant non-recurring costs impacted profitability.
- Plans to reset US operations and diversify manufacturing to reduce tariff impact.
- Expansion focus on the Middle East and Asia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$21 |
FY25 Results Announcement
|
29 Aug 2025 9:35AM |
$0.098 |
$0.075 |
fallen by
23.47%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- GALE Pacific Limited faced geopolitical and tariff challenges in FY25.
- Revenue decreased by 1.2% to $172 million.
- EBITDA declined by 15.5% to $12 million, with a net loss of $5.2 million.
- Americas revenue fell by 11.3%, impacted by consumer confidence and tariffs.
- Australia/New Zealand revenue grew 7.6% due to strong summer sales.
- Developing markets saw a 14.4% revenue increase from Middle East and Europe projects.
- Non-recurring costs totaled $5.4 million due to ERP and leadership transitions.
- FX expenses impacted profits by $2.1 million due to currency movements.
- Focus on streamlining U.S. operations and diversifying manufacturing for future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$21 |
FY25 Results Announcement
|
29 Aug 2025 9:35AM |
$0.098 |
$0.075 |
fallen by
23.47%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- GALE Pacific faced geopolitical and tariff-related challenges in the US.
- Revenue decreased by 1.2% in FY25.
- Net loss after tax was reported at AUD 5.2 million.
- Revenue grew by 7.6% in Australia/New Zealand.
- Revenue increased by 14.4% in developing markets.
- GALE Pacific aims to restructure US operations and diversify manufacturing footprint in FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$16 |
Atomo Investor Webinar Presentation
|
29 Aug 2025 9:35AM |
$0.018 |
$0.018 |
fallen by
0%
|
|
| MedAdvisor Limited (MDR) ORDINARY FULLY PAID |
Health Care |
- |
Board changes to align with current scale
|
29 Aug 2025 9:35AM |
$0.056 |
$0.022 |
fallen by
60.71%
|
|
Call 1300 880 160
Start a chat
Schedule a call
